RxDoctor Payments Data

Uri Napchan, MD

Neurology · Middletown, NYNPI 1710045844

Payments from drug & device makers

$205,960in general payments, 2019–2025

Across 568 payments — averaging $362.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$85K
  • Lilly USA, LLC$56K
  • Amgen$25K
  • Eisai Inc.$16K
  • Teva Pharmaceuticals USA, Inc.$16K
  • Lundbeck LLC$6K
  • plus $649 from 12 others

What the payments were for

  • Consulting fees$15,7458%
  • Speaking & faculty fees$171,03383%
  • Grants$880%
  • Travel & lodging$8,9384%
  • Food & beverage$10,0065%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,960 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$479,847
Medicare patients
464
Services billed
62,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate153$286,180
VyeptiEptinezumab-Jjmr37$200,138
UbrelvyUbrogepant144$193,700
QuliptaAtogepant123$137,836
Emgality PenGalcanezumab-Gnlm78$70,778
BotoxOnabotulinumtoxina37$42,470
ReyvowLasmiditan Succinate49$36,022
Ajovy AutoinjectorFremanezumab-Vfrm39$35,024
Ajovy SyringeFremanezumab-Vfrm26$21,806
Aimovig AutoinjectorErenumab-Aooe30$21,723
HorizantGabapentin Enacarbil21$16,334
ZavzpretZavegepant Hcl14$14,889
Gabapentin161$2,649
Lamotrigine OdtLamotrigine12$2,533
Memantine Hcl117$2,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$85,229$374,005304 claims
PfizerNurtec Odt, Zavzpret$300$301,068167 claims
Lundbeck LLCVyepti$6,225$200,13837 claims
Lilly USA, LLCReyvow$56,048$36,02249 claims
Upsher-smith Laboratories LLCTopiramate$23$1,507128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →